stoxline Quote Chart Rank Option Currency Glossary
  
ALX Oncology Holdings Inc. (ALXO)
8.44  -0.09 (-1.06%)    06-13 16:00
Open: 8.55
High: 8.75
Volume: 532,798
  
Pre. Close: 8.53
Low: 8.34
Market Cap: 440(M)
Technical analysis
2024-06-13 4:41:30 PM
Short term     
Mid term     
Targets 6-month :  16.27 1-year :  20.44
Resists First :  13.93 Second :  17.5
Pivot price 10.1
Supports First :  8.15 Second :  6.78
MAs MA(5) :  8.64 MA(20) :  11.13
MA(100) :  13.71 MA(250) :  10.32
MACD MACD :  -1.7 Signal :  -1.5
%K %D K(14,3) :  4.8 D(3) :  6.3
RSI RSI(14): 27.5
52-week High :  17.82 Low :  3.93
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALXO ] has closed above bottom band by 28.5%. Bollinger Bands are 70.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.81 - 8.89 8.89 - 8.94
Low: 8.16 - 8.27 8.27 - 8.34
Close: 8.32 - 8.49 8.49 - 8.6
Company Description

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Headline News

Mon, 10 Jun 2024
HC Wainwright Reaffirms Buy Rating for ALX Oncology (NASDAQ:ALXO) - MarketBeat

Mon, 10 Jun 2024
ALX Oncology (NASDAQ:ALXO) Earns Buy Rating from HC Wainwright - Defense World

Sun, 09 Jun 2024
Vestal Point Capital LP Takes Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - MarketBeat

Thu, 06 Jun 2024
Alx oncology president & cso sells $168k in company stock By Investing.com - Investing.com

Sun, 02 Jun 2024
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 ... - GlobeNewswire

Wed, 29 May 2024
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 52 (M)
Shares Float 21 (M)
Held by Insiders 2 (%)
Held by Institutions 93.9 (%)
Shares Short 3,360 (K)
Shares Short P.Month 3,690 (K)
Stock Financials
EPS -3.72
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.26
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -44.8 %
Return on Equity (ttm) -82.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.36
Qtrly Earnings Growth 0 %
Operating Cash Flow -140 (M)
Levered Free Cash Flow -80 (M)
Stock Valuations
PE Ratio -2.28
PEG Ratio 0
Price to Book value 2.58
Price to Sales 0
Price to Cash Flow -3.14
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android